Horizon Pharma Soars On Big Q3 Beat, Guidance Raise
Specialty drugmaker Horizon Pharma (HZNP) jumped in Friday trade after it pounded Wall Street’s Q3 estimates and raised its guidance. Horizon’s adjusted earnings soared 268% over the year-earlier quarter to 70 cents a share, some 30 cents above analysts’ consensus, according to Thomson Reuters. Sales tripled to $226.4 million, more than $40 million past consensus. Horizon added $85 million to its full-year revenue guidance, now $750 million to